MACS GMP CD3 pure is a GMP-grade soluble CD3 (OKT3) antibody for ex vivo T cell activation.
MACS GMP Products are for research use and ex vivo cell culture processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.
The CD3 antibody (OKT3) recognizes the human CD3 antigen which is expressed on mature T cells, thymocytes and NKT cells. CD3 is associated with the T cell receptor (TCR) and induces the signaling cascade for effector functions of the T cell.
Activation and proliferation of T cells can be induced by interaction of the T cell receptor (TCR) with peptide-MHC complexes expressed on the surface of antigen presenting cells (APC). T cell activation can also be achieved by agonistic stimulation with the CD3 antibody binding to the TCR complex.
The antibody is suitable for ex vivo T cell activation and expansion and is already established in a variety of clinical protocols for ex vivo T cell stimulation. For example, the transduction of T cells with viral vectors requires the previous activation, which can be achieved by stimulation with CD3 antibody1,2. Furthermore, T cell subsets, such as tumor infiltrating lymphocytes (TILs) can be expanded3, or T cells polyclonally activated by CD3 stimulation.
The CD3 antibody can be combined with CD28 antibody, which gives an additional costimulatory stimulus4.
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.
- Pule, M. A. et al. (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14(11): 1264–1270.
- Ciceri, F. et al. (2009) Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 10(5): 489–500.
- Dudley, M. E. et al. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10): 2346–2357.
- Lamers et al. (2002) Protocol for gene transduction and expansion of human T lymphocytes for clinical immunogene therapy of cancer. Cancer Gene Ther. 9(7): 613–623.
Please follow this link
to search for certificates by lot number.